Pemetrexed Intravenous and Tenofovir Alafenamide
Determining the interaction of Pemetrexed Intravenous and Tenofovir Alafenamide and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Tenofovir can affect kidney function and may increase the blood levels and effects of PEMEtrexed when used together. You may be more likely to develop serious side effects of PEMEtrexed such as anemia, bleeding problems, infections, and nerve damage. Contact your doctor if you experience severe nausea and vomiting, diarrhea, paleness of skin, fatigue, dizziness, fainting, unusual bleeding or bruising, fever, chills, body aches, flu-like symptoms, mouth ulcers or sores, and/or numbness, burning or tingling in your hands and feet. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.
MANAGEMENT: Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy. Pemetrexed should not be administered to patients whose creatinine clearance is below 45 mL/min.
- "Product Information. Alimta (pemetrexed)." Lilly, Eli and Company, Indianapolis, IN.
Generic Name: pemetrexed
Brand name: Alimta
Synonyms: Pemetrexed, PEMEtrexed
Generic Name: tenofovir alafenamide
Brand name: Vemlidy
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Pemetrexed Intravenous-Tenofovir Alafenamide Fumarate
- Pemetrexed Intravenous-Tenofovir Disoproxil Fumarate
- Pemetrexed Intravenous-Tenofovir Disoproxil Fumarate Oral Powder
- Pemetrexed Intravenous-Tenofovir Disoproxil Fumarate Tablets
- Pemetrexed Intravenous-Tenoretic
- Pemetrexed Intravenous-Tenoretic 100
- Tenofovir Alafenamide-Pemoline
- Tenofovir Alafenamide-Penbutolol
- Tenofovir Alafenamide-Penciclovir
- Tenofovir Alafenamide-Penciclovir topical
- Tenofovir Alafenamide-Penicillamine
- Tenofovir Alafenamide-Penicillamine Capsules